結核治療薬市場- 世界の産業規模、シェア、動向、機会、予測、疾患タイプ別、治療法別、投与経路別、剤形別、流通チャネル別、地域別、競合別、2020-2030年

結核治療薬の世界市場は、2024年に21億8,000万米ドルと評価され、2030年には29億4,000万米ドルに達し、CAGR 5.05％で成長すると予測されています。

感染症治療における重要なセグメントとして位置づけられるこの市場は、特に薬剤耐性結核の増加により、持続的な世界的需要から利益を得ています。歴史的に利益率が低いにもかかわらず、結核治療薬は公衆衛生上の価値が高く、長期的な商業的可能性を秘めています。政府、保健機関、製薬企業は、革新的な結核治療法の開発をますます優先するようになっており、その背景には、世界の患者数の安定と、ドナーや公的機関からの多額の資金援助があります。次世代医薬品の開発、特に二次治療薬の開発が増加する中、費用対効果のバランスを取り、規制状況を乗り切り、戦略的協力関係を構築できる企業は、持続可能な競争力を確保する上で有利な立場にあります。

市場促進要因

結核の世界の高負担

主な市場課題

医薬品開発のための不十分な資金と限られた商業的インセンティブ

主要市場動向

より短く、より効果的な治療レジメンへのシフト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 結核治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 病気の種類別（活動性結核、潜在性結核）
  • 治療法別（第一選択療法、第二選択療法）
  • 投与経路別（経口、非経口、その他）
  • 剤形別（錠剤、カプセル剤、注射剤、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の結核治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の結核治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の結核治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の結核治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの結核治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の結核治療薬市場：SWOT分析

第14章 競合情勢

• AstraZeneca PLC
• Johnson & Johnson Services, Inc.
• Eli Lilly and Company
• Mylan Inc.
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Pfizer Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Tuberculosis Therapeutics Market was valued at USD 2.18 billion in 2024 and is projected to reach USD 2.94 billion by 2030, growing at a CAGR of 5.05%. Positioned as a crucial segment within infectious disease treatment, this market benefits from persistent global demand, especially due to the rising incidence of drug-resistant TB. Despite its historically low profit margins, the TB therapeutics space offers significant public health value and long-term commercial potential. Governments, health agencies, and pharmaceutical firms are increasingly prioritizing the development of innovative TB treatments, supported by consistent global case numbers and substantial funding from donors and public institutions. With next-generation drug development-particularly in second-line therapies-on the rise, companies that can balance cost-effectiveness, navigate regulatory landscapes, and build strategic collaborations are well-placed to secure a sustainable competitive edge.

Key Market Drivers

High Global Burden of Tuberculosis

The global tuberculosis (TB) burden remains a primary driver of market expansion. WHO data indicates that 10.8 million people contracted TB in 2023, up from 10.7 million in 2022, highlighting a rising trend. This sustained prevalence ensures ongoing demand for both first-line and second-line TB therapies, reinforcing the market's stability. For pharmaceutical companies, this represents a significant opportunity to scale drug portfolios and foster collaborations with public health organizations. The high incidence, particularly in regions with limited healthcare infrastructure, underscores the necessity for scalable treatment solutions, positioning the TB therapeutics market as a reliable avenue for both healthcare impact and commercial returns.

Key Market Challenges

Inadequate Funding and Limited Commercial Incentives for Drug Development

The concentration of TB cases in low- and middle-income countries often means that treatment relies on public funding and donor support rather than private investment. This results in limited profitability, discouraging pharmaceutical companies from prioritizing TB drug development. With constrained pricing models, complex regulatory pathways, and minimal patent protection, the return on investment for TB drugs is typically low. Further, the extended timelines of clinical trials and dependency on external funding inhibit innovation. Without enhanced incentives such as co-development frameworks or market guarantees, TB therapeutics are likely to lag behind other disease areas in terms of pharmaceutical innovation.

Key Market Trends

Shift Toward Shorter, More Effective Treatment Regimens

There is a growing emphasis on developing shorter, more tolerable TB treatment regimens to improve adherence and outcomes. Novel combinations, such as the 6-month BPaL regimen, are transforming the landscape by reducing the treatment burden compared to traditional 18-24-month protocols. Supported by WHO endorsements and donor-funded initiatives, these advancements are generating increased interest in next-generation therapies. Pharmaceutical companies capable of innovating in fixed-dose combinations and new drug mechanisms stand to benefit from this shift, as these regimens often command higher per-patient value due to better efficacy, reduced side effects, and enhanced patient compliance.

Key Market Players

• AstraZeneca PLC
• Johnson & Johnson Services, Inc.
• Eli Lilly and Company
• Mylan Inc.
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Pfizer Inc.

Report Scope:

In this report, the Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tuberculosis Therapeutics Market, By Disease Type:

• Active TB
• Latent TB

Tuberculosis Therapeutics Market, By Therapy:

• First-Line Therapy
• Second-Line Therapy

Tuberculosis Therapeutics Market, By Route of Administration:

• Oral
• Parenteral
• Others

Tuberculosis Therapeutics Market, By Dosage Form:

• Tablets
• Capsules
• Injection
• Others

Tuberculosis Therapeutics Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Tuberculosis Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tuberculosis Therapeutics Market.

Available Customizations:

Global Tuberculosis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Tuberculosis Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Active TB, Latent TB)
  • 5.2.2. By Therapy (First-Line Therapy, Second-Line Therapy)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By Dosage Form (Tablets, Capsules, Injection, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Tuberculosis Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Therapy
  • 6.2.3. By Route of Administration
  • 6.2.4. By Dosage Form
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tuberculosis Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Dosage Form
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Tuberculosis Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Dosage Form
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Tuberculosis Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Dosage Form
      • 6.3.3.2.5. By Distribution Channel

7. Europe Tuberculosis Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Therapy
  • 7.2.3. By Route of Administration
  • 7.2.4. By Dosage Form
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tuberculosis Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Dosage Form
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. United Kingdom Tuberculosis Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Dosage Form
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. Italy Tuberculosis Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Dosage Form
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. France Tuberculosis Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Dosage Form
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Tuberculosis Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Dosage Form
      • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Tuberculosis Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Therapy
  • 8.2.3. By Route of Administration
  • 8.2.4. By Dosage Form
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Tuberculosis Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Dosage Form
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Tuberculosis Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Dosage Form
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Tuberculosis Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Dosage Form
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Tuberculosis Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Dosage Form
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Tuberculosis Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Dosage Form
      • 8.3.5.2.5. By Distribution Channel

9. South America Tuberculosis Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Therapy
  • 9.2.3. By Route of Administration
  • 9.2.4. By Dosage Form
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Tuberculosis Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Dosage Form
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. Argentina Tuberculosis Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Dosage Form
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. Colombia Tuberculosis Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Dosage Form
      • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Tuberculosis Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Therapy
  • 10.2.3. By Route of Administration
  • 10.2.4. By Dosage Form
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Tuberculosis Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Dosage Form
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Saudi Arabia Tuberculosis Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Dosage Form
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. UAE Tuberculosis Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Dosage Form
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Tuberculosis Therapeutics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. AstraZeneca PLC
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Johnson & Johnson Services, Inc.
• 14.3. Eli Lilly and Company
• 14.4. Mylan Inc.
• 14.5. Teva Pharmaceutical Industries Ltd
• 14.6. Sanofi
• 14.7. Novartis AG
• 14.8. Sun Pharmaceutical Industries Ltd
• 14.9. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer